Please Wait
Applying Filters...
menu
    • menu
    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    SPI Pharma has been solving formulation challenges using superior functional materials.

    Virtual Booth

    Contact Supplier

    Interquim comes from an international group of 50 companies active in the pharma, hospital, diagnostics, fine chemicals & feed sectors.

    Virtual Booth

    Contact Supplier

    Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.

    Virtual Booth

    Contact Supplier

    FAMAR CDMO- From early development to commercial manufacturing.

    Virtual Booth

    Contact Supplier

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    Menu

    Annamycin

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Moleculin Gets EU Nod To Recruit For MIRACLE Ph3 AML Trial
    Moleculin Gets EU Nod To Recruit For MIRACLE Ph3 AML Trial

    11 Feb 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/moleculin-receives-first-country-approval-in-europe-to-begin-recruiting-for-the-miracle-phase-3-rr-acute-myeloid-leukemia-aml-pivotal-trial-302372939.html

    PR NEWSWIRE
    11 Feb 2025
    Share Share
    Moleculin's Annamycin Phase 2 AML Data Surpasses Top Competitors
    Moleculin's Annamycin Phase 2 AML Data Surpasses Top Competitors

    08 Jan 2025

    // #N/A

    https://www.prnewswire.com/news-releases/moleculin-highlights-development-progress-of-annamycin-phase-2-data-outperforms-billion-dollar-assets-in-aml-phase-3-data-readouts-in-2025--2026-302345069.html

    #N/A
    08 Jan 2025
    Share Share
    Moleculin Reports Q2 2024 Results And Provides Corporate Update
    Moleculin Reports Q2 2024 Results And Provides Corporate Update

    14 Aug 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/moleculin-reports-second-quarter-2024-financial-results-and-provides-corporate-update-302221619.html

    PR NEWSWIRE
    14 Aug 2024
    Share Share
    Moleculin Completes End of Phase 2 Meeting with FDA for Annamycin in AML
    Moleculin Completes End of Phase 2 Meeting with FDA for Annamycin in AML

    10 Jul 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/moleculin-completes-end-of-phase-2-meeting-with-fda-for-annamycin-in-aml-302192692.html

    PR NEWSWIRE
    10 Jul 2024
    Share Share
    Moleculin US Patent For Annamycin Lipid Delivery Tech
    Moleculin US Patent For Annamycin Lipid Delivery Tech

    09 May 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/moleculin-announces-us-patent-issue-notification-for-lipid-based-delivery-technology-for-annamycin-302140466.html

    PR NEWSWIRE
    09 May 2024
    Share Share
    Moleculin Presents Positive Annamycin Data
    Moleculin Presents Positive Annamycin Data

    10 Apr 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/moleculin-announces-presentation-of-positive-data-demonstrating-high-anti-cancer-activity-of-annamycin-and-non-cardiotoxic-properties-302112418.html

    PR NEWSWIRE
    10 Apr 2024
    Share Share